The PD-1/PD-L1 pathway is essential for maintaining immune tolerance, and pembrolizumab, by blocking PD-1, disrupts this tolerance, potentially leading to autoimmunity; losing regulatory control over T-cells can heighten autoreactive T-cell responses, contributing to MMP pathology [148]– [149]. Here, CD274 is linked to Autoimmunity.